Neuronoff Secures $5 Million in DOD and NIH Funding to Advance Minimally Invasive Neuromodulation Platform
- Cadiz Salazar
- Feb 5
- 2 min read
Neuronoff, Inc., a trailblazer in minimally invasive neuromodulation, has hit a major milestone—securing $5 million in funding to propel its groundbreaking Injectrode® technology forward. With $1.73 million from the Department of Defense (DOD) for a clinical trial targeting neurogenic bladder after spinal cord injury, and $3.2 million from the National Institutes of Health (NIH) for preclinical research on overactive bladder (OAB), Neuronoff is driving innovation in neuromodulation like never before.
Transforming Spinal Cord Injury Care
The DOD-backed clinical trial, conducted in partnership with the University of Texas Health Science Center, will explore Injectrode Tibial Nerve Stimulation (iTNS) as a game-changing approach for neurogenic bladder management in spinal cord injury (SCI). Over three years, the study will evaluate the safety and effectiveness of Injectrode’s implantation along the tibial nerve, tracking treatment impact over an 8-week protocol.
The trial will assess how iTNS influences the need for overactive bladder medications—measuring both complete medication elimination and percentage reduction from baseline. As the first human clinical trial in SCI for this technology, these findings will be crucial for FDA presubmission discussions and future pivotal studies.
“Neurogenic bladder remains a significant challenge for SCI patients, with existing treatments often falling short due to side effects and long-term unreliability,” said Dr. Argyrios Stampas, lead investigator of the trial. “Injectrode’s needle-based, minimally invasive delivery method could revolutionize therapy accessibility while reducing risks for patients.”
A Bold Leap in Overactive Bladder Treatment
In parallel, a $3.2 million NIH grant will fuel a five-year preclinical study on Injectrode’s potential in treating OAB. This initiative, led by the University of Wisconsin, Case Western Reserve University, and Massachusetts General Hospital, aims to refine Injectrode’s innovative electrode system for precise nerve targeting.
“This funding enables us to optimize a groundbreaking injection tool with embedded fiber optics for visualization, making electrode placement more accurate and effective,” said Dr. Kip Ludwig, lead PI of the OAB study. “This method could redefine neuromodulation, improving long-term outcomes while reducing complications.”
A Vision for the Future
About Neuronoff
Headquartered in Cleveland, Ohio, Neuronoff is revolutionizing neuromodulation with minimally invasive, drug-free alternatives for chronic conditions. Its flagship product, Injectrode®, is redefining treatment possibilities for pain, autonomic, bladder, cardiac, and inflammatory disorders.
ความคิดเห็น